Lung Cancer
Treatment Options
If you have lung cancer, call us. We can help you review the type, stage, biomarkers, treatment history and options that are available.
Newly diagnosed, in treatment, facing recurrence or Stage 4 disease—your case deserves an individualized review and a direct conversation.
Call 1.800.923.7878The introductory call with our Patient Care Team is free. Medical recommendations require a physician consultation.
Talk With Our Lung Cancer Patient Care Team
Tell us what you are facing. Our Patient Care Team will follow up personally, explain the consultation process and help you understand the next step. The introductory call is free.
A direct, individualized review of the diagnosis and the options that are available
If you have lung cancer, call us. Sunridge Medical helps patients understand the type of lung cancer, the stage, biomarkers, treatment history, symptoms and the questions that should be addressed next. The free introductory call is designed to get you to the right conversation quickly.
There is no single “lung cancer treatment.” A newly diagnosed lung adenocarcinoma, limited-stage small cell lung cancer, unresectable Stage 3 non-small cell lung cancer and recurrent metastatic disease are different clinical situations. A useful plan begins with the exact facts—not a package of therapies.
Non-small cell and small cell lung cancer are treated differently
Non-small cell lung cancer (NSCLC)
NSCLC includes adenocarcinoma, squamous cell carcinoma and other less common subtypes. Treatment may involve surgery, radiation, chemotherapy, immunotherapy, targeted therapy or a clinical trial, depending on stage, resectability, tumor biology and health.
Explore NSCLC treatment questions →Small cell lung cancer (SCLC)
SCLC often grows and spreads quickly. It is commonly described as limited-stage or extensive-stage. Chemotherapy, immunotherapy and radiation are central treatment categories; surgery is considered only in uncommon, very early situations.
Explore SCLC treatment questions →Pathology matters. “Pulmonary cancer,” “lung carcinoma” and “lung cancer” are broad terms and do not provide enough information to select treatment.
Five parts of the record can change the treatment discussion
Pathology
Confirm the cancer type and subtype. If the diagnosis is based on a small biopsy, ask whether enough tissue remains for required testing.
Stage and resectability
Review the primary tumor, lymph nodes and every known site of spread, and whether local treatment is technically reasonable.
Biomarkers
For NSCLC, molecular testing and PD-L1 can identify treatment questions that cannot be answered by stage alone.
- Previous chemotherapy, immunotherapy, radiation or surgery
- Best response and why each treatment stopped
- Breathing symptoms, oxygen needs, pain and neurologic symptoms
- Smoking history, lung function and other medical conditions
- Current medicines and supplements
- Patient goals, priorities and treatment tolerance
The available categories depend on type, stage and tumor biology
Surgery and local treatment
Surgery can be central for selected early NSCLC. Radiation—including highly focused techniques in appropriate settings—and other local procedures may be used when surgery is not appropriate or for selected sites of disease.
Systemic treatment
Chemotherapy, immunotherapy, targeted therapy and clinical trials treat cancer beyond one visible site. The sequence and combination depend on the diagnosis, biomarkers, previous treatment and health.
Stage 3 care
Stage 3 lung cancer is heterogeneous. Resectability, lymph-node pattern, pathology, molecular findings and ability to tolerate combined treatment can change the plan.
Stage 4 / metastatic care
Metastatic lung cancer may involve one distant site or widespread disease. Tumor biology, symptoms, brain involvement, previous response and local-treatment opportunities all matter.
Biomarker testing can be treatment-defining in non-small cell lung cancer
Modern NSCLC decisions often require more than a pathology label. Depending on the setting, a care team may review tumor molecular testing, a blood-based assay, PD-L1 and whether the sample was adequate. Results may identify a targeted therapy, help select immunotherapy, support a clinical-trial search or show that a particular option is unlikely to help.
- Was broad molecular testing performed?
- Is the complete report available?
- Was testing done on tissue, blood or both?
- Is PD-L1 reported separately?
- Does the result change the current decision?
- Should retesting be discussed after progression?
Support the patient without blurring the purpose of treatment
People search for “alternative lung cancer treatment,” “natural lung cancer therapy,” “alternatives to chemotherapy” and “holistic cancer care” for understandable reasons: fear of side effects, a difficult previous experience, a need for more control or a desire to improve quality of life. These terms must be handled honestly.
There may be medically appropriate alternatives
Depending on the case, surgery, radiation, targeted therapy, immunotherapy, a different systemic regimen or a clinical trial may be an available alternative within an evidence-based treatment pathway. That is different from promising that cancer can be treated naturally.
Integrative care needs a defined goal
Support may address nutrition, strength, sleep, anxiety, pain, nausea, neuropathy, breathing rehabilitation, medication interactions or treatment tolerance. An intervention that helps a symptom should not be described as though it controls the tumor.
No diet, herb or supplement has been proven to cure lung cancer. Natural products can interact with chemotherapy, immunotherapy, radiation, anticoagulants and other medicines. Every product should be reviewed in context.
The questions change as the disease changes
New diagnosis
Confirm pathology, stage, resectability and required biomarkers before making a major treatment decision whenever the clinical timeline allows.
Stage 3
Clarify whether surgery is possible, which lymph nodes are involved, how chemotherapy and radiation are sequenced and whether consolidation or biomarker-guided questions apply.
Stage 4
Define every site of spread, symptoms that require urgent care, brain imaging, molecular results, systemic options and whether any limited sites deserve local review.
Recurrence or progression
Reconstruct what was tried, the response, toxicities and the reason treatment ended. Updated tissue or blood testing and clinical trials may become relevant.
Population survival statistics describe groups treated in the past; they cannot predict one person’s outcome. A responsible second opinion should explain the uncertainty, goals, benefits and risks of the options that are available.
Breathing, strength, symptoms and daily function deserve active attention
Shortness of breath, cough, pain, fatigue, appetite loss, weight change, anxiety and reduced conditioning can affect both quality of life and treatment tolerance. Symptom management and palliative care can be provided alongside active cancer treatment; they are not the same as giving up.
- Breathing symptoms and oxygen needs
- Pain, cough or coughing blood
- Nutrition, hydration and weight trends
- Fatigue, sleep and physical function
- Nausea, bowel changes and neuropathy
- Emotional, family and practical support
Bring what is available—do not wait to call because a record is missing
- Pathology report and biopsy procedure note
- CT, PET and brain MRI reports and image files
- Molecular, genomic and PD-L1 reports
- Surgery and radiation summaries
- Every systemic treatment with dates and response
- Recent blood work and pulmonary testing
- Medication and supplement list
- A short timeline and the questions that matter most
Talk with our Patient Care Team for free
If you are facing lung cancer, call us. We can help you organize the diagnosis, reports and questions that deserve a closer review. The introductory call is free and does not obligate you to schedule a consultation.
Explore the guide that fits your diagnosis
Frequently asked questions
What is the difference between NSCLC and SCLC?
They are different groups of lung cancer with different behavior, staging conventions and typical treatment strategies. The pathology report should identify the type before treatment is selected.
Can Stage 4 lung cancer be treated?
Yes. Stage 4 lung cancer is treated, but the goals and options vary. Biomarkers, pathology, sites of spread, symptoms, health and prior treatment influence the plan.
Does every lung cancer patient need biomarker testing?
Comprehensive biomarker testing is especially important in NSCLC. The exact testing needed depends on the subtype, stage, available tissue and clinical decision.
Are there alternatives to chemotherapy?
There may be other evidence-based treatment categories—such as surgery, radiation, immunotherapy, targeted therapy or clinical trials—in appropriate cases. No natural product should be assumed to replace indicated cancer treatment.
Can I get a second opinion without leaving my oncologist?
Yes. A second opinion can confirm the current plan, identify questions or help you understand tradeoffs while you continue working with your established oncology team.
Is the introductory call free?
Yes. The Patient Care Team call is free. It is not a medical consultation or diagnosis; it helps you understand the process and whether physician review may be appropriate.
Sources and important context
- Non-Small Cell Lung Cancer Treatment (PDQ®)
- Small Cell Lung Cancer Treatment (PDQ®)
- Biomarker Testing for Cancer Treatment
- Finding Cancer Care and Seeking a Second Opinion
- Cancer Therapy Interactions With Foods and Dietary Supplements
Medical information disclaimer: This page provides general education and does not replace individualized diagnosis or treatment. Lung cancer decisions require review of the exact pathology, stage, biomarkers, prior treatment, medicines, symptoms and overall health. Do not start, stop or replace cancer treatment based on website content.
Integrative Lung Cancer Care in Scottsdale, Arizona
Sunridge Medical provides physician-directed integrative support for people facing lung cancer at our Scottsdale clinic. We serve patients from Scottsdale, Phoenix, the Greater Phoenix area and people traveling to Arizona for care.
Care can be coordinated around histology, stage, molecular findings, breathing, strength, systemic treatment, radiation and quality-of-life goals.
14200 N Northsight Blvd, Suite 160
Scottsdale, Arizona 85260
Map, parking and directions →
Call 1-800-923-7878 for a free introductory conversation about your diagnosis and next steps.
Our team can help you understand scheduling and plan a visit to the Scottsdale clinic.